Funda Demirtas Korkmaz1,2, Irem Dogan Turacli3, Guldal Esendagli4, Abdullah Ekmekci5. 1. Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Ankara, Turkey. fundakorkmz@gmail.com. 2. Department of Medical Biology, Faculty of Medicine, Giresun University, Giresun, 28100, Turkey. fundakorkmz@gmail.com. 3. Department of Medical Biology, Faculty of Medicine, Ufuk University, Ankara, Turkey. 4. Department of Medical Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey. 5. Department of Medical Biology and Genetics, Faculty of Medicine, Gazi University, Ankara, Turkey.
Abstract
OBJECTIVE: FoxM1 transcription factor contributes to tumor metastasis and poor prognosis in many cancers including triple-negative breast cancer (TNBC). In this study, we examined the effects of FoxM1 inhibitor Thiostrepton (THIO) alone or in combination with MEK inhibitor Selumetinib (SEL) on metastatic parameters in vitro and in vivo. METHODS: Cell viability was determined by MTT assay. Immunoblotting and immunohistochemistry was used to assess metastasis-related protein expressions in 4T1 cells and its allograft tumor model in BALB/c mice. In vivo uPA activity was determined by enzymatic methods. RESULTS: Both inhibitors were effective on the expressions of FoxM1, ERK, p-ERK, Twist, E-cadherin, and Vimentin alone or in combination in vitro. THIO significantly decreased 4T1 cell migration and changed the cell morphology from mesenchymal-like to epithelial-like structure. THIO was more effective than in combination with SEL in terms of metastatic protein expressions in vivo. THIO alone significantly inhibited mean tumor growth, decreased lung metastasis rate and tumor foci, however, no significant changes in these parameters were observed in the combined group. Immunohistochemically, FoxM1 expression intensity was decreased with THIO and its combination with SEL in the tumors. CONCLUSIONS: This study suggests that inhibiting FoxM1 as a single target is more effective than combined treatment with MEK in theTNBC allograft model. The therapeutic efficacy of THIO should be investigated with further studies on appropriate drug delivery systems.
OBJECTIVE: FoxM1 transcription factor contributes to tumor metastasis and poor prognosis in many cancers including triple-negative breast cancer (TNBC). In this study, we examined the effects of FoxM1 inhibitor Thiostrepton (THIO) alone or in combination with MEK inhibitor Selumetinib (SEL) on metastatic parameters in vitro and in vivo. METHODS: Cell viability was determined by MTT assay. Immunoblotting and immunohistochemistry was used to assess metastasis-related protein expressions in 4T1 cells and its allograft tumor model in BALB/c mice. In vivo uPA activity was determined by enzymatic methods. RESULTS: Both inhibitors were effective on the expressions of FoxM1, ERK, p-ERK, Twist, E-cadherin, and Vimentin alone or in combination in vitro. THIO significantly decreased 4T1 cell migration and changed the cell morphology from mesenchymal-like to epithelial-like structure. THIO was more effective than in combination with SEL in terms of metastatic protein expressions in vivo. THIO alone significantly inhibited mean tumor growth, decreased lung metastasis rate and tumor foci, however, no significant changes in these parameters were observed in the combined group. Immunohistochemically, FoxM1 expression intensity was decreased with THIO and its combination with SEL in the tumors. CONCLUSIONS: This study suggests that inhibiting FoxM1 as a single target is more effective than combined treatment with MEK in theTNBC allograft model. The therapeutic efficacy of THIO should be investigated with further studies on appropriate drug delivery systems.
Authors: P Khongkow; A R Gomes; C Gong; E P S Man; J W-H Tsang; F Zhao; L J Monteiro; R C Coombes; R H Medema; U S Khoo; E W-F Lam Journal: Oncogene Date: 2015-05-11 Impact factor: 9.867
Authors: Brian D Lehmann; Bojana Jovanović; Xi Chen; Monica V Estrada; Kimberly N Johnson; Yu Shyr; Harold L Moses; Melinda E Sanders; Jennifer A Pietenpol Journal: PLoS One Date: 2016-06-16 Impact factor: 3.240